Insilico to present the advances in AI for healthcare at the Africa Healthcare Extension Summit

Credit: Insilico Medicine

Monday, June 25, 2018, Rockville, MD – Insilico Medicine, a Rockville-based company specializing in the application of next-generation artificial intelligence for drug discovery, biomarker development and aging research, announces the talk of its Africa AI, Blockchain and Longevity Consultant, Iraneus Ogu, at the Africa Healthcare Extension Summit, June 27, 2018, organized by Verve Management in Nairobi, Kenya.

Ogu's presentation "Converging Artificial Intelligence and Blockchain to Accelerate Healthcare Developments in Africa" will be devoted to the recent advances of AI in healthcare and explore how this technology tends to accelerate the development of healthcare services in Africa. The presentation will also focus on the latest applications of Blockchain in healthcare and drug discovery that can be utilized for local African healthcare issues.

"The digital revolution in healthcare led to the immense amount of data that are generated daily, and these data could be channeled towards the better products in healthcare. However, many people in the world, especially in Africa, do not yet realize the value of their personal data including the medical records. At the same time, there is a clear need to develop better solutions to many global healthcare challenges in addition to more local challenges in places like Africa. Herein we could converge advances in next-generation artificial intelligence and blockchain to accelerate developments in many aspects of healthcare and beyond", said Iraneus Ogu, Africa AI, Blockchain and Longevity Consultant of Insilico Medicine, Inc.

"We are very happy to present our work at the Africa Healthcare Extension Summit, which brings together many African thought leaders in healthcare. The topic of AI and Blockchain for healthcare is rapidly gaining popularity and we are happy to be at the leading edge of research and one of the innovation drivers in this area", said Alex Zhavoronkov, PhD, the founder and CEO of Insilico Medicine, Inc.

Artificial Intelligence and Blockchain for Healthcare and Drug Discovery is turning into a credible industry and received recognition from the world's most prominent industry analysts including Frost & Sullivan and CB Insights.

Africa Healthcare Extension Summit is bringing together the various stakeholders in the medical and healthcare ecosystem for an exchange of ideas and best practices to support project development in upgrading, expanding and construction of hospitals across the continent. The organisers aim to unite the invited experts to discuss sustainable hospital development, regulatory framework, partnerships, local and international case studies, technology development, HR training and skillset enhancement, e-health and healthcare financing, funding and government incentives. The event will be held on June 26-27.


Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. The paper published in Molecular Pharmaceutics in 2016 demonstrated the first proof of concept of the application of deep neural networks for predicting the therapeutic class of the molecule using the transcriptional response data, received the American Chemical Society Editors' Choice Award. One of the latest paper published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients.

For further information, images or interviews, please contact:

Contact: Qingsong Zhu, PhD
[email protected]


Official Forum Website:


About Insilico Medicine, Inc

Insilico Medicine is an artificial intelligence company headquartered at in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan and Korea sourced through hackathons and competitions. The company and its scientists is dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine and aging research.

Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.

In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video:

                           <p><strong>Media Contact</strong></p>    <p>Qingsong Zhu<br />[email protected]<br />410-710-9674<br /> @InSilicoMeds